Bond.az White LogoBond.az Black Logo

Reddit Stock Rating Boosted by App Growth

Citizens maintains Market Outperform on Reddit stock with $240 target. App installs surged 129% YoY, driving advertising growth.

Grace Lewis
ByGrace Lewis- Senior Editor
|
0

Bond.az - Citizens reiterated its Market Outperform rating and $240 price target on Reddit stock (NYSE:RDDT). The stock currently trades at $141.67, down 32% over the past six months.

Reddit’s app install volume increased 129% year-over-year. Max app campaigns reduced cost per acquisition by 15% and boosted result volume by 28% in early testing.

Analyst Andrew Boone noted that the shift to automated app-performance budgets expands Reddit’s advertising total addressable market.

In recent news, Reddit reported Q1 2026 revenue of $663 million, up 69% YoY, and net income of $204 million, up 680%.

More News
Today / 11:03
|
631

Jefferies Raises SentinelOne Price Target to $24

Jefferies raised SentinelOne price target to $24 on margin outlook, maintaining Buy rating. Stock at $18.71, NNARR growth expected. Analyst sees H2 margin expansion.

0
Today / 11:02
|
566

ThinkEquity Initiates Atlas with Buy

ThinkEquity initiates Atlas Technical Consultants with a Buy rating and $15 target. The firm highlights the value of the Brazil critical-minerals option.

0
Today / 10:33
|
492

Wolfe Research Reaffirms Ionis Stock Outperform Rating

Wolfe Research reiterates Outperform rating on Ionis Pharmaceuticals stock. Analysis of Arrowhead competition and financial results.

0
Today / 10:31
|
510

BTIG reiterates Uber Buy rating after Delivery Hero bid

BTIG reaffirms Uber Buy rating with $100 target after Delivery Hero bid. Stock seen as undervalued.

0
Today / 10:30
|
550

BTIG Reiterates Neutral on Affirm Stock

BTIG reiterates Neutral on Affirm stock amid credit trends. Analysis of delinquencies, growth prospects, and analyst targets.

0
Today / 10:02
|
707

Mizuho Cuts Intuit Target on TurboTax Weakness

Mizuho cuts Intuit target to $500 on TurboTax weakness; shares fall 20%. Read more on Bond.az.

0
Today / 08:00
|
677

Leerink Reaffirms Eli Lilly Stock Rating on Gene Therapy

Leerink reaffirms Eli Lilly stock rating with Outperform and $1,119 target, citing promising gene therapy data from VERVE-102 trial. Bond.az covers the latest.

0
Today / 06:02
|
602

Goldman Sachs Initiates Hemab Buy

Goldman Sachs initiates Hemab Therapeutics with buy rating. Sutacimig and HMB-002 target rare bleeding disorders.

0
Today / 06:01
|
425

Morgan Stanley Initiates Avalyn Pharma with Overweight

Morgan Stanley initiates Avalyn Pharma with Overweight rating and $53 target. The inhaled therapies AP01 and AP02 show promise in pulmonary fibrosis.

0
Today / 06:00
|
496

Goldman Sachs Backs Seaport Stock

Goldman Sachs initiates coverage on Seaport Therapeutics with an Early-Stage Biotech rating. Learn about the company's platform and financials.

0
Yesterday / 15:32
|
644

Jefferies Initiates Avalyn Pharma with Buy

Jefferies initiates Avalyn Pharma with Buy rating and $52 price target. AP01 shows promising efficacy in progressive lung diseases.

0
Yesterday / 15:31
|
924

Jefferies Initiates Pershing Square USA Buy

Jefferies initiates Buy rating on Pershing Square USA (PSUS), highlighting the fund's strategy, discount, and lack of performance fee.

0
...